• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ENDOLOGIX AFX; BIFURCATED STENT GRAFT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ENDOLOGIX AFX; BIFURCATED STENT GRAFT Back to Search Results
Model Number BA28-80/I20-40
Medical Device Problem Code Material Puncture/Hole (1504)
Health Effect - Clinical Code Failure of Implant (1924)
Date of Event 01/10/2019
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
The device involved in the event will not be returned for evaluation as it remains implanted in the patient.If additional information pertinent to the incident is obtained, a follow-up report will be submitted.
 
Event or Problem Description
The patient was initially implanted with a bifurcated stent graft and a suprarenal stent graft extension to treat an abdominal aortic aneurysm (aaa).Approximately 2.5 years post initial procedure, a type iii endoleak was reported.A secondary procedure was completed.The physician elected to reline the original implanted devices with the ovation abdominal stent graft system to treat the reported event.As of the date of this report, there have been no additional patient sequelae reported.
 
Event or Problem Description
Additional information: the reported type 3 endoleak was reported to be a type 3b endoleak the patient was reported as doing well post intervention and the intervention was reported as successful in resolving the type 3b endoleak.
 
Additional Manufacturer Narrative
The manufacturing lot evaluation confirmed all devices met specifications prior to release.The device was not returned as the device remains implanted therefore no evaluation was completed.At the completion of the clinical assessment, due to the lack of relevant medical imaging, clinical was unable to find substantial evidence to support the following events of 3b endoleak.Procedure related harms, device, user, procedure or anatomy relatedness of this complaint could not be determined.No additional investigation of this reported event is planned however if additional information pertinent to the incident is obtained, a follow-up report will be submitted.Endologix will continue to monitor this complaint and similar complaints in the event further investigation is needed.Correction: conclusion code: remove code 11.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
AFX
Common Device Name
BIFURCATED STENT GRAFT
Manufacturer (Section D)
ENDOLOGIX
2 musick
irvine CA 92618
MDR Report Key8316686
Report Number2031527-2019-00077
Device Sequence Number1663411
Product Code MIH
UDI-Device Identifier00818009012265
UDI-Public(01)00818009012265(17)190308
Combination Product (Y/N)N
Initial Reporter StateAZ
Initial Reporter CountryUS
PMA/510(K) Number
P040002
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2016
Reporter Type Manufacturer
Report Source company representative,health
Initial Reporter Occupation Physician
Type of Report Initial,Followup
Report Date (Section B) 01/10/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date03/08/2019
Device Model NumberBA28-80/I20-40
Device Lot Number1412031008
Was Device Available for Evaluation? Yes
Initial Date Received by Manufacturer 01/10/2019
Supplement Date Received by Manufacturer02/20/2019
Initial Report FDA Received Date02/07/2019
Supplement Report FDA Received Date04/11/2019
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
Yes
Patient Sequence Number1
Concomitant Medical Products
and Therapy/Usage Dates
SUPRARENAL EXTENSION, LOT 1469355009; SUPRARENAL EXTENSION, LOT 1469355009
Outcome Attributed to Adverse Event Required Intervention;
Patient Age85 YR
-
-